The Group's generics activities in the Italian market focus primarily on the sales company EG S.p.A., Milan. Another company, Crinos S.p.A., Milan, is primarily responsible for branded products.
In Italy, the Group recorded sales growth of 6% to EUR 41.1 million (1-3/2011: EUR 38.7 million) in the first quarter of 2012.
Sales achieved by STADA with generics in the Italian market in the reporting period increased by 10% to EUR 31.4 million (1-3/2011: EUR 28.6 million). Generics thus contributed 76% (1-3/2011: 74%) to local STADA sales.
Sales recorded by STADA in Italy with branded products declined by 4% as expected to EUR 9.7 million (1-3/2011: EUR 10.1 million). Branded products thereby had a 24% share of STADA’s local sales (1-3/2011: 26%).
For financial year 2012, the Executive Board expects a renewed sales increase in Italy with an operating profitability which will again be at about Group average.